Menu
Other / Miscellaneous

Glomerulonephritis (leading to ESRD)

Glomerulonephritis (Leading to End-Stage Renal Disease): A Comprehensive Medical Guide

1. Comprehensive Introduction & Overview

Glomerulonephritis (GN) represents a diverse group of renal diseases characterized by inflammation and damage to the glomeruli, the tiny filtering units within the kidneys. These delicate structures are responsible for filtering waste products and excess fluid from the blood, a process vital for maintaining overall physiological homeostasis. When glomeruli become inflamed or damaged, their filtering capacity is compromised, leading to a spectrum of clinical manifestations ranging from asymptomatic hematuria and proteinuria to life-threatening acute kidney injury (AKI) or progressive chronic kidney disease (CKD).

The profound significance of glomerulonephritis lies in its potential to culminate in End-Stage Renal Disease (ESRD), a devastating condition where the kidneys irreversibly lose their ability to function, necessitating renal replacement therapy such as dialysis or kidney transplantation for survival. ESRD places an immense burden on individuals, healthcare systems, and society, underscoring the critical importance of early diagnosis, precise classification, and aggressive management of GN. This comprehensive guide aims to provide an exhaustive, authoritative overview of glomerulonephritis, detailing its clinical definition, intricate pathophysiology, diagnostic modalities, and long-term prognostic implications.

2. Deep-dive into Technical Specifications / Mechanisms

2.1. Clinical Definition

Glomerulonephritis is fundamentally an inflammatory process affecting the glomerulus, which comprises a tuft of capillaries enclosed within Bowman's capsule. This inflammation can be primary, originating within the kidney itself, or secondary, as a manifestation of systemic diseases. The hallmark of glomerular injury is often the disruption of the glomerular filtration barrier, leading to abnormal leakage of proteins (proteinuria) and red blood cells (hematuria) into the urine. Over time, persistent inflammation and injury can lead to glomerulosclerosis, a scarring process that irreversibly destroys nephrons, ultimately leading to a decline in glomerular filtration rate (GFR) and progression to ESRD.

2.2. Etiology: The Diverse Origins of Glomerulonephritis

The causes of GN are remarkably varied, broadly categorized into primary and secondary forms:

Primary Glomerulonephritis:

These forms of GN are intrinsic to the kidney, with the glomeruli being the primary target of disease.
* IgA Nephropathy (Berger's Disease): The most common primary GN worldwide, characterized by IgA immune complex deposition in the mesangium. Often presents with recurrent macroscopic hematuria, particularly after upper respiratory or gastrointestinal infections.
* Focal Segmental Glomerulosclerosis (FSGS): Characterized by segmental sclerosis in some (focal) glomeruli. It can be primary (idiopathic), genetic, or secondary to other conditions (e.g., obesity, HIV, drug-induced). A major cause of nephrotic syndrome in adults.
* Membranous Nephropathy (MN): Characterized by subepithelial immune complex deposition and thickening of the glomerular basement membrane. Most commonly caused by autoantibodies against the M-type phospholipase A2 receptor (PLA2R) in primary forms. A leading cause of nephrotic syndrome in non-diabetic adults.
* Minimal Change Disease (MCD): The most common cause of nephrotic syndrome in children. Characterized by effacement of podocyte foot processes on electron microscopy, with minimal changes on light microscopy. Highly responsive to corticosteroids.
* Post-Infectious Glomerulonephritis (PIGN): Typically follows a streptococcal infection (e.g., pharyngitis, impetigo) but can be caused by other bacteria or viruses. Characterized by immune complex deposition and diffuse proliferative inflammation.
* Rapidly Progressive Glomerulonephritis (RPGN): A severe, aggressive form characterized by rapid loss of renal function (over days to weeks) and the presence of crescents in >50% of glomeruli on biopsy. It is a clinicopathological syndrome rather than a single disease and includes:
* Anti-GBM Disease (Goodpasture's Syndrome): Autoantibodies target the glomerular basement membrane, often associated with pulmonary hemorrhage.
* Immune Complex RPGN: Associated with systemic lupus erythematosus, PIGN, or IgA nephropathy.
* Pauci-Immune RPGN: Associated with ANCA-associated vasculitides (e.g., Granulomatosis with Polyangiitis, Microscopic Polyangiitis, Eosinophilic Granulomatosis with Polyangiitis).
* Membranoproliferative Glomerulonephritis (MPGN) / C3 Glomerulopathy: Characterized by mesangial and endothelial cell proliferation and thickening of the glomerular basement membrane. Can be immune complex-mediated or complement-mediated (C3 glomerulopathy).

Secondary Glomerulonephritis:

These are glomerular diseases that occur as a complication or manifestation of systemic illnesses.
* Lupus Nephritis: Renal involvement in Systemic Lupus Erythematosus (SLE), categorized by ISN/RPS classification (Classes I-VI) based on biopsy findings.
* Diabetic Nephropathy: While not typically considered an inflammatory GN, it is the most common cause of CKD and ESRD, characterized by glomerular hypertrophy, mesangial expansion, and basement membrane thickening due to chronic hyperglycemia.
* Vasculitis: Systemic inflammation of blood vessels, often leading to pauci-immune RPGN (e.g., ANCA-associated vasculitides).
* Amyloidosis: Deposition of abnormal protein fibrils (amyloid) in the glomeruli.
* Cryoglobulinemic Glomerulonephritis: Associated with cryoglobulin deposition, often linked to Hepatitis C infection.
* HIV-Associated Nephropathy (HIVAN): A specific form of FSGS rapidly progressing to ESRD in HIV-infected individuals.
* Drug-Induced GN: Certain medications can induce glomerular injury (e.g., NSAIDs, pamidronate).

2.3. Pathophysiology: The Mechanisms of Glomerular Injury

The pathogenesis of GN is largely immune-mediated, involving a cascade of events leading to glomerular inflammation and damage.

  1. Immune Complex Deposition: Circulating antigen-antibody complexes can deposit in the glomeruli (subendothelial, subepithelial, or mesangial spaces). Alternatively, antibodies can form in situ by binding to antigens planted within the glomerulus or to intrinsic glomerular components.
  2. Complement Activation: Deposited immune complexes or autoantibodies activate the complement system, leading to the generation of potent inflammatory mediators (e.g., C3a, C5a) and the formation of the Membrane Attack Complex (MAC, C5b-9). This causes direct cellular injury and attracts inflammatory cells.
  3. Cellular Infiltration and Release of Mediators: Neutrophils, monocytes/macrophages, and T-lymphocytes are recruited to the inflamed glomeruli. These cells release a plethora of pro-inflammatory cytokines (e.g., TNF-Ξ±, IL-1, IL-6), chemokines, reactive oxygen species, and proteases, which directly damage glomerular cells (podocytes, mesangial cells, endothelial cells) and the glomerular basement membrane (GBM).
  4. Glomerular Cell Injury and Dysfunction:
    • Podocyte Injury: Damage to podocytes (visceral epithelial cells) leads to effacement of foot processes, disruption of the slit diaphragm, and loss of negative charge, resulting in proteinuria.
    • Mesangial Cell Proliferation and Matrix Expansion: Mesangial cells proliferate and produce excessive extracellular matrix, leading to mesangial expansion, which can compromise capillary patency.
    • Endothelial Cell Damage: Injury to glomerular endothelial cells can lead to microthrombosis and further inflammation.
    • GBM Thickening/Rupture: Immune deposits and inflammation can thicken or rupture the GBM, further impairing filtration.
  5. Crescent Formation (in RPGN): In severe, rapidly progressive forms, parietal epithelial cells proliferate and infiltrate macrophages accumulate in Bowman's space, forming characteristic crescents. These crescents compress the glomerular tuft, severely impairing filtration and rapidly destroying the glomerulus.
  6. Progression to Fibrosis and Sclerosis: Chronic or severe acute glomerular injury triggers a maladaptive repair process. Sustained inflammation, growth factor release (e.g., TGF-Ξ²), and activation of myofibroblasts lead to the deposition of collagen and other extracellular matrix components, resulting in glomerulosclerosis (scarring of glomeruli) and tubulointerstitial fibrosis. This irreversible damage reduces the number of functional nephrons and progressively lowers the GFR, ultimately culminating in ESRD.

2.4. Clinical Staging/Grading

While there isn't a universal staging system exclusively for Glomerulonephritis, its progression and severity are assessed using several frameworks:

  • Specific Biopsy Classifications: For certain types of GN, detailed histological classifications are crucial for grading severity and guiding treatment.
    • Lupus Nephritis (ISN/RPS Classification): Categorizes LN into six classes (I-VI) based on the location and extent of lesions (e.g., Class III: Focal Proliferative LN, Class IV: Diffuse Proliferative LN, Class V: Membranous LN).
    • IgA Nephropathy (Oxford Classification): Uses MEST-C score (Mesangial hypercellularity, Endocapillary hypercellularity, Segmental glomerulosclerosis, Tubular atrophy/interstitial fibrosis, Crescents) to predict prognosis.
    • Diabetic Nephropathy: Graded histologically based on severity of mesangial expansion, GBM thickening, and nodular sclerosis.
  • Chronic Kidney Disease (CKD) Stages: Glomerulonephritis often leads to CKD. The severity of kidney function impairment is universally staged based on estimated GFR (eGFR) and albuminuria. ESRD corresponds to CKD G5.
CKD Stage GFR (mL/min/1.73 mΒ²) Description
G1 β‰₯ 90 Normal or high GFR
G2 60-89 Mildly decreased GFR
G3a 45-59 Mildly to moderately decreased GFR
G3b 30-44 Moderately to severely decreased GFR
G4 15-29 Severely decreased GFR
G5 < 15 End-Stage Renal Disease (ESRD) or kidney failure
  • Activity vs. Chronicity on Biopsy: Renal biopsy reports often distinguish between active inflammatory lesions (e.g., cellular crescents, endocapillary proliferation) which are potentially reversible with treatment, and chronic, irreversible lesions (e.g., global glomerulosclerosis, tubular atrophy, interstitial fibrosis), which indicate permanent damage and predict poorer prognosis.

3. Extensive Clinical Indications & Usage

3.1. Standard Presentation

The clinical presentation of GN is highly variable, depending on the type, severity, and chronicity of the disease. It can manifest as:

  • Acute Nephritic Syndrome:
    • Hematuria: Often macroscopic (visible to the naked eye, "cola-colored" urine) or microscopic. Red blood cell casts are pathognomonic.
    • Proteinuria: Usually sub-nephrotic (<3.5 g/day), but can be higher.
    • Hypertension: Due to fluid retention and activation of the renin-angiotensin-aldosterone system.
    • Edema: Periorbital swelling, peripheral edema, due to fluid retention.
    • Oliguria/Azotemia: Reduced urine output and elevated blood urea nitrogen (BUN) and creatinine, indicating acute kidney injury.
  • Nephrotic Syndrome:
    • Massive Proteinuria: >3.5 g/day (or >40 mg/hr/mΒ² in children).
    • Hypoalbuminemia: Serum albumin <3.0 g/dL.
    • Severe Edema: Generalized anasarca (swelling), often pitting, due to low oncotic pressure.
    • Hyperlipidemia: Elevated cholesterol and triglycerides.
    • Lipiduria: Lipids in the urine.
    • Increased risk of thrombosis and infection.
  • Rapidly Progressive Glomerulonephritis (RPGN):
    • Acute nephritic syndrome with a rapid decline in renal function over days to weeks.
    • Often severe constitutional symptoms like malaise, fever, weight loss.
    • Can be associated with systemic symptoms if part of a vasculitis (e.g., hemoptysis in Goodpasture's, sinusitis/purpura in ANCA vasculitis).
  • Asymptomatic Urinary Abnormalities:
    • Isolated microscopic hematuria and/or proteinuria detected on routine urinalysis. Often indicative of early or mild GN (e.g., IgA nephropathy).
  • Chronic Glomerulonephritis:
    • Insidious onset, often discovered incidentally through elevated creatinine, hypertension, or persistent proteinuria/hematuria over months to years.
    • Progressive decline in renal function, often leading to symptoms of CKD (fatigue, nausea, pruritus, anemia, bone disease).

3.2. Differential Diagnosis

Distinguishing GN from other renal or systemic conditions presenting with similar symptoms is crucial.

Symptom/Finding Glomerulonephritis Differential Other Conditions to Consider
Hematuria IgA nephropathy, PIGN, RPGN Urolithiasis, UTI, Renal cell carcinoma, Polycystic Kidney Disease, Trauma, Coagulopathy
Proteinuria All types of GN Diabetic nephropathy, Hypertensive nephrosclerosis, Orthostatic proteinuria, Amyloidosis, Preeclampsia
Edema Nephrotic syndrome, AKI Congestive heart failure, Liver cirrhosis, Venous insufficiency, Hypothyroidism, Drug-induced
Acute Kidney Injury RPGN, severe acute GN Prerenal azotemia (dehydration, heart failure), Postrenal obstruction (BPH, stones), Acute Tubular Necrosis (sepsis, toxins)
Hypertension All types of GN Primary hypertension, Renal artery stenosis, Pheochromocytoma, Primary aldosteronism
Systemic Symptoms Vasculitis, Lupus nephritis Systemic infections, Other autoimmune diseases, Malignancies

3.3. Key Diagnostic Tests

The diagnostic workup for suspected GN is comprehensive, aiming to confirm the diagnosis, classify the specific type, assess severity, and identify potential underlying causes.

  • Laboratory Tests:
    • Urinalysis with Microscopy: Essential for detecting hematuria (especially dysmorphic red cells), proteinuria, and pathognomonic red blood cell casts.
    • Quantitative Proteinuria: 24-hour urine protein collection or urine protein-to-creatinine ratio (UPCR) to quantify protein loss.
    • Serum Creatinine and BUN: To assess renal function and calculate eGFR.
    • Serum Albumin: To assess nutritional status and confirm hypoalbuminemia in nephrotic syndrome.
    • Electrolytes: To detect imbalances (e.g., hyperkalemia, metabolic acidosis).
    • Complement Levels (C3, C4): Reduced levels suggest immune complex-mediated GN (e.g., PIGN, lupus nephritis, cryoglobulinemia).
    • Autoantibody Panel:
      • ANA (Antinuclear Antibodies): For Systemic Lupus Erythematosus.
      • Anti-dsDNA (Anti-double-stranded DNA): Highly specific for SLE.
      • ANCA (Antineutrophil Cytoplasmic Antibodies): For ANCA-associated vasculitides (c-ANCA/PR3-ANCA for Granulomatosis with Polyangiitis; p-ANCA/MPO-ANCA for Microscopic Polyangiitis).
      • Anti-GBM Antibodies: For Anti-GBM disease.
      • Anti-PLA2R Antibodies: For primary membranous nephropathy.
    • Infectious Workup:
      • ASO Titer, Anti-DNase B: For recent streptococcal infection (PIGN).
      • Hepatitis B & C serology, HIV testing: For secondary GNs associated with these infections.
      • Cryoglobulins: For cryoglobulinemic GN.
  • Imaging Studies:
    • Renal Ultrasound: Provides information on kidney size, cortical thickness, presence of hydronephrosis (to rule out obstruction), and signs of chronicity (small, echogenic kidneys). Doppler ultrasound can assess renal blood flow.
  • Renal Biopsy (Gold Standard):
    • A percutaneous biopsy of kidney tissue is often mandatory for definitive diagnosis, classification, assessment of disease activity and chronicity, and guiding therapy.
    • Tissue is examined by:
      • Light Microscopy (LM): Reveals structural changes (e.g., proliferation, sclerosis, crescent formation).
      • Immunofluorescence (IF): Detects immune deposits (IgA, IgG, IgM, C3, C1q) and their distribution.
      • Electron Microscopy (EM): Provides ultrastructural detail (e.g., podocyte foot process effacement, location of immune deposits, GBM thickening).

4. Risks, Side Effects, or Contraindications

4.1. Risks and Complications of Glomerulonephritis

Untreated or progressive GN carries significant risks, ultimately impacting patient morbidity and mortality:

  • Progression to ESRD: The most severe complication, requiring dialysis or kidney transplantation.
  • Hypertension: Often difficult to control, contributing to cardiovascular disease risk.
  • Cardiovascular Disease: Patients with CKD due to GN have a significantly increased risk of heart attack, stroke, and heart failure.
  • Infections: Especially in nephrotic syndrome (e.g., spontaneous bacterial peritonitis) and due to immunosuppressive therapy.
  • Thromboembolism: Particularly in nephrotic syndrome due to hypercoagulability (loss of antithrombin III, increased fibrinogen).
  • Acute Kidney Injury (AKI): Rapid decline in renal function, often requiring temporary dialysis.
  • Electrolyte Imbalances: Hyperkalemia, hyperphosphatemia, metabolic acidosis.
  • Anemia: Due to reduced erythropoietin production.
  • Bone and Mineral Disorders: Renal osteodystrophy.

4.2. Side Effects of Treatment

Management of GN often involves immunosuppressive medications, which carry their own spectrum of side effects:

  • Corticosteroids (e.g., Prednisone): Hyperglycemia, hypertension, weight gain, osteoporosis, cataracts, glaucoma, increased infection risk, mood changes, gastric ulcers.
  • Cyclophosphamide: Bone marrow suppression (leukopenia, thrombocytopenia), hemorrhagic cystitis, infertility, increased risk of malignancy.
  • Mycophenolate Mofetil (MMF): Gastrointestinal upset (nausea, diarrhea), bone marrow suppression, increased infection risk.
  • Calcineurin Inhibitors (e.g., Cyclosporine, Tacrolimus): Nephrotoxicity (direct kidney damage), hypertension, neurotoxicity (tremor), hirsutism (cyclosporine), gingival hyperplasia (cyclosporine), diabetes.
  • Rituximab: Infusion reactions, increased infection risk (especially viral), progressive multifocal leukoencephalopathy (PML) rarely.
  • Angiotensin-Converting Enzyme (ACE) Inhibitors / Angiotensin Receptor Blockers (ARBs): Hyperkalemia, cough (ACEIs), acute kidney injury (especially in renal artery stenosis).

4.3. Contraindications

Specific treatments for GN have contraindications:

  • Immunosuppressants: Generally contraindicated in active, severe infections. Dose adjustments or temporary discontinuation may be required.
  • Live Vaccines: Should be avoided in patients on significant immunosuppression.
  • ACEIs/ARBs: Should be used with caution or avoided in severe hyperkalemia, bilateral renal artery stenosis, or severe AKI.
  • Pregnancy: Certain immunosuppressants (e.g., cyclophosphamide, mycophenolate mofetil) are teratogenic and contraindicated during pregnancy.

4.4. Long-Term Prognosis

The long-term prognosis of glomerulonephritis is highly variable and depends on numerous factors:

  • Type of GN: Some types, like minimal change disease in children, often have an excellent prognosis with treatment. Others, like rapidly progressive GN or advanced FSGS, carry a high risk of progression to ESRD.
  • Severity at Presentation: Patients presenting with severe AKI, extensive crescent formation, or significant tubulointerstitial fibrosis on biopsy tend to have a poorer prognosis.
  • Response to Treatment: Early and adequate response to immunosuppressive therapy significantly improves outcomes.
  • Presence of Chronicity: The extent of irreversible damage (glomerulosclerosis, tubular atrophy, interstitial fibrosis) on renal biopsy is a strong predictor of long-term kidney survival.
  • Control of Modifiable Factors: Aggressive management of hypertension, proteinuria, and diabetes can slow disease progression.
  • Comorbidities: Coexisting conditions like cardiovascular disease, diabetes, and obesity can worsen outcomes.

Despite advancements in treatment, many forms of GN can progress to ESRD, necessitating lifelong renal replacement therapy. Even in those who do not reach ESRD, the increased burden of CKD and its associated complications, particularly cardiovascular disease, significantly impacts long-term morbidity and mortality. Regular monitoring, adherence to treatment, and a multidisciplinary approach are paramount for optimizing patient outcomes.

5. Massive FAQ Section

Q1: What exactly is Glomerulonephritis?

A1: Glomerulonephritis (GN) is a group of diseases characterized by inflammation and damage to the glomeruli, the tiny filters in your kidneys. These filters are crucial for removing waste and excess fluid from your blood. When they are inflamed, they can't function properly, leading to various symptoms and potentially kidney failure.

Q2: How does Glomerulonephritis lead to End-Stage Renal Disease (ESRD)?

A2: Persistent inflammation and injury in glomerulonephritis cause scarring (sclerosis) of the glomeruli. Over time, this scarring destroys more and more of the kidney's filtering units (nephrons). As the number of functional nephrons decreases, the kidneys lose their ability to filter blood effectively, leading to a progressive decline in kidney function that eventually culminates in ESRD, requiring dialysis or a kidney transplant.

Q3: What are the common symptoms of Glomerulonephritis?

A3: Symptoms vary widely but can include:
* Hematuria: Blood in the urine, which may appear cola-colored or rusty.
* Proteinuria: Foamy urine due to excess protein.
* Edema: Swelling in the face (especially around the eyes), hands, feet, and ankles.
* Hypertension: High blood pressure.
* Fatigue, weakness, loss of appetite, nausea: General symptoms of declining kidney function.
* Decreased urine output.
Some forms may be asymptomatic and only detected through routine urine tests.

Q4: Is Glomerulonephritis curable?

A4: The curability of glomerulonephritis depends heavily on its specific type and the stage at which it's diagnosed. Some forms, like minimal change disease, are highly responsive to treatment and can achieve full remission. Others, particularly rapidly progressive forms, may be controlled but not cured, often requiring long-term management to slow progression. Unfortunately, some types are progressive and lead to ESRD despite treatment.

Q5: What are the main types of Glomerulonephritis?

A5: Glomerulonephritis is classified into many types, broadly categorized as primary (originating in the kidney) or secondary (due to systemic diseases). Common types include:
* Primary: IgA Nephropathy, Focal Segmental Glomerulosclerosis (FSGS), Membranous Nephropathy, Minimal Change Disease, Post-Infectious GN, and Rapidly Progressive GN (RPGN) syndromes.
* Secondary: Lupus Nephritis (due to SLE), Diabetic Nephropathy, ANCA-associated vasculitis, and Glomerulonephritis related to infections like Hepatitis B/C or HIV.

Q6: How is Glomerulonephritis diagnosed?

A6: Diagnosis typically involves:
* Urinalysis: To detect blood, protein, and red blood cell casts in the urine.
* Blood Tests: To measure kidney function (creatinine, BUN, eGFR), serum albumin, complement levels, and specific autoantibodies (e.g., ANA, ANCA, anti-GBM, anti-PLA2R) to identify the underlying cause.
* Imaging: Renal ultrasound to assess kidney size and structure.
* Kidney Biopsy: This is the gold standard, where a small piece of kidney tissue is examined under a microscope to definitively classify the type of GN, assess its severity, and guide treatment.

Q7: What is a renal biopsy and why is it important?

A7: A renal biopsy is a procedure where a small sample of kidney tissue is taken, usually with a needle, and examined under light, immunofluorescence, and electron microscopy. It is critically important because it provides the most precise diagnosis of the type of glomerulonephritis, helps determine the extent of active inflammation versus irreversible scarring, and guides the choice of specific immunosuppressive therapies. Without a biopsy, accurate diagnosis and targeted treatment are often challenging.

Q8: What are the treatment options for Glomerulonephritis?

A8: Treatment is highly individualized based on the type and severity of GN. It often involves:
* Immunosuppressive Medications: Corticosteroids (e.g., prednisone), cyclophosphamide, mycophenolate mofetil, calcineurin inhibitors (cyclosporine, tacrolimus), and biologics (e.g., rituximab) to suppress the immune system and reduce inflammation.
* Blood Pressure Control: ACE inhibitors or ARBs are commonly used to lower blood pressure and reduce proteinuria, protecting the kidneys.
* Diuretics: To manage edema and fluid retention.
* Dietary Modifications: Low-sodium, low-protein, and potassium/phosphate restrictions as kidney function declines.
* Dialysis or Kidney Transplantation: For patients who progress to ESRD.

Q9: Can Glomerulonephritis be prevented?

A9: Most primary forms of glomerulonephritis are not preventable as they are autoimmune in nature or have unknown causes. However, secondary forms might be partially preventable or their progression slowed by:
* Managing underlying conditions: Strict control of diabetes, lupus, and high blood pressure.
* Prompt treatment of infections: Especially streptococcal infections to prevent post-infectious GN.
* Avoiding nephrotoxic drugs: When possible.

Q10: What is the role of diet in managing Glomerulonephritis?

A10: Diet plays a crucial role, especially as kidney function declines.
* Sodium Restriction: Helps control blood pressure and edema.
* Protein Management: While protein intake may need to be restricted in advanced CKD, it's important to maintain adequate nutrition, especially in nephrotic syndrome where protein is lost in urine.
* Potassium and Phosphate Restriction: May be necessary as kidney function worsens to prevent electrolyte imbalances.
* Fluid Restriction: Often required in cases of significant edema or fluid overload.
A registered dietitian specializing in kidney disease can provide personalized dietary guidance.

Q11: What is the prognosis for someone with Glomerulonephritis?

A11: The prognosis is highly variable. Some individuals achieve complete remission and live normal lives, while others experience progressive kidney damage, eventually leading to ESRD. Factors influencing prognosis include the specific type of GN, its severity at diagnosis